FDA Grants Orphan Drug Status to Orion's ODM-212

The US Food and Drug Administration has granted orphan drug designation to ODM-212, an oral pan-TEAD inhibitor developed by Orion Pharma, for the treatment of mesothelioma. The designation, announced on April 20, 2026, recognizes the therapy’s potential to address a rare cancer with limited treatment options.

ODM-212 works by blocking TEAD transcription factors, a family of proteins that drive cancer cell growth when the Hippo signaling pathway is disrupted. The drug disrupts YAP-TEAD protein interactions and inhibits TEAD auto-palmitoylation, cutting off an oncogenic signal that is frequently active in mesothelioma tumors.

What Is ODM-212

ODM-212 is an oral, small-molecule pan-TEAD inhibitor. The drug targets all four TEAD transcription factors rather than a single isoform. Preclinical research suggests that pan-TEAD inhibitors outperform isoform-specific ones because mesothelioma tumors use different TEAD family members in different ways.

The Hippo signaling pathway regulates organ size and cell growth. In many mesothelioma tumors, Hippo signaling is disrupted, and the co-activator YAP teams up with TEAD proteins in the cell nucleus to drive uncontrolled growth.

ODM-212 interrupts that process in three ways. It blocks TEAD transcription factors directly, disrupts the YAP-TEAD interaction, and inhibits a chemical modification called TEAD auto-palmitoylation that the protein needs to function.

ODM-212 joins a group of Hippo-targeted drugs now being tested in mesothelioma. MesoWatch previously reported on IK-930 data at ESMO, the VT3989 program, and the IAG933 discontinuation. At the ESMO Congress in 2025, IAG933 and VT3989 produced the first clinical evidence that TEAD inhibitors can achieve disease control in people with heavily pre-treated mesothelioma.

What Orphan Drug Status Means

FDA orphan drug designation is granted to treatments for diseases that affect fewer than 200,000 people in the United States. Mesothelioma qualifies because roughly 3,300 new cases are diagnosed each year.

The designation provides three benefits for the drug developer:

• Tax credits for clinical trial costs
• Exemption from FDA user fees
• Up to seven years of US market exclusivity if the drug is approved

In a statement accompanying the announcement, Orion Chief Medical Officer Praveen Aanur called the designation “an important milestone for the ODM-212 program.”

Where It Fits in Treatment

ODM-212 is being studied in the TEADES trial (NCT06725758), a global, open-label, multi-center Phase 1/2 study. The trial is enrolling adults with malignant pleural mesothelioma, epithelioid hemangioendothelioma, and other advanced solid tumors who have progressed on standard therapies and have no further treatment options available.

Orion initiated the Phase 2 portion in December 2025 with the first patient dosed. The primary endpoints of the trial are safety and tolerability. Secondary endpoints include overall response rate, progression-free survival, and overall survival.

Because ODM-212 is open only to patients who have exhausted other options, the earliest readouts will tell researchers whether the drug is safe and whether it can produce measurable disease control in people who have run out of alternatives. No efficacy data are available yet.

For anyone considering a clinical trial, a conversation with the treating oncology team is the usual starting point. Eligibility depends on tumor type, prior therapy, and other medical factors that only the treating team can assess. Broader context on current options is available in the MesoWatch mesothelioma treatment landscape and clinical trials landscape report.